Kineta, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kineta, Inc. (KA) is a clinical-stage biotechnology company that develops novel immunotherapies targeting cancer immune resistance mechanisms, including immunosuppression, exhausted T cells, and poor tumor immunogenicity, with a focus on innate immunity in immuno-oncology. The company offers a pipeline featuring KVA12123, a fully human monoclonal antibody blocking VISTA (V-domain Ig suppressor of T cell activation) administered intravenously every two weeks, evaluated in Phase 1/2 trials for advanced solid tumors such as non-small cell lung cancer, colorectal cancer, ovarian cancer, renal cell carcinoma, and head and neck squamous cell carcinoma, both as monotherapy and in combination with pembrolizumab; and a preclinical anti-CD27 agonist monoclonal antibody immunotherapy. Kineta operates primarily in the United States, serving private, government, and industry partners in oncology, with historical interests in neuroscience and biodefense; it maintains headquarters in Mercer Island, Washington, and was founded in 2006 or 2007 as Lecura, Inc., later merging with Yumanity Therapeutics. In June 2025, TuHURA Biosciences, Inc. completes the acquisition of Kineta, converting Kineta shares into TuHURA common stock and renaming KVA12123 as TBS-2025, a Phase 2-ready VISTA inhibitor planned for combination trials in NPM1-mutated acute myeloid leukemia and potential antibody-drug conjugates targeting myeloid-derived suppressor cells; this follows a February 2024 restructuring with workforce reductions and clinical trial enrollment suspension to explore strategic alternatives, alongside prior partnerships with entities like Pfizer, Genentech, Wellcome, Samsung Biologics, and a clinical trial collaboration with Merck for KVA12123 plus KEYTRUDA.
TuHURA Biosciences Completes Acquisition of Kineta
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc. - HURA
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1
Kineta, Inc Transitioning from Nasdaq to OTC Markets
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
Kineta Announces Restructuring and Exploration of Strategic Alternatives
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium